Mostrar el registro sencillo

dc.contributor.authorFonseca Santos, Martaes_ES
dc.contributor.authorBailen, Rebecaes_ES
dc.contributor.authorLopez Godino, Orianaes_ES
dc.contributor.authorHerruzo Delgado, Beatrizes_ES
dc.contributor.authorBermudez, Maria Aranzazues_ES
dc.contributor.authorGarcía Cadenas, Irenees_ES
dc.contributor.authorHuguet Mas, Maríaes_ES
dc.contributor.authorFerra Coll, Christellees_ES
dc.contributor.authorEsquirol, Albertes_ES
dc.contributor.authorCortés Rodriguez, Maríaes_ES
dc.contributor.authorYáñez San Segundo, Lucrecia es_ES
dc.contributor.authorPascual Cascon, María Jesúses_ES
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2025-03-06T11:34:54Z
dc.date.available2025-03-06T11:34:54Z
dc.date.issued2024es_ES
dc.identifier.issn0041-1337es_ES
dc.identifier.issn1534-6080es_ES
dc.identifier.urihttps://hdl.handle.net/10902/35908
dc.description.abstractBackground: Chronic graft-versus-host disease (cGVHD) is a cause of late morbidity and nonrelapse mortality (NRM) after allogenic hematopoietic stem cell transplantation (allo-HSCT). Although studies evaluating haploidentical allo-HSCT (haplo-HSCT) using posttransplant cyclophosphamide (PTCy) demonstrate lower cGVHD rates, comprehensive data describing the clinical profile, risk factors, or outcomes of cGVHD within this platform are scarce. Methods: We conducted a retrospective multicenter analysis of 389 consecutive patients who underwent haplo-HSCT PTCy in 7 transplant centers of the Spanish Group Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH-TC) between 2008 and 2020 describing incidence, clinical profile, risk factors, and cGVHD outcomes. Results: Ninety-five patients of 389 developed cGVHD. Our data revealed that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis and that the strongest predictor for cGVHD was previous acute GVHD (P = 0.031). Also, recipient age 60 y (P = 0.044) was protective against cGVHD. Moreover, patients with moderate cGVHD had longer event-free survival at 3 y than other patients (P = 0.016) and a lower relapse rate at 3 y (P = 0.036). Conclusions: Our results support the fact that the incidence and severity of cGVHD are lower than those reported for HLA-identical transplantation with conventional prophylaxis. In this series, patients who develop moderate cGVHD after haplo-HSCT PTCy had a higher overall survival and event-free survival, and lower relapse, suggesting higher graft-versus-leukemia effect. Although this is the largest series focused on characterizing cGVHD in haplo-HSCT PTCy, further prospective studies are needed to confirm the findings.es_ES
dc.format.extent10 p.es_ES
dc.language.isoenges_ES
dc.publisherLippincott Williams & Wilkinses_ES
dc.rightsCopyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceTransplantation, 2024, 108(10), 2134-2143es_ES
dc.titleCharacterization of chronic graft-versus-host disease after haploidentical stem cell transplantation with posttransplant cyclophosphamide: a study on behalf of GETH-TCes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://doi.org/10.1097/TP.0000000000005034es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.1097/TP.0000000000005034es_ES
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This
is an open-access article distributed under the terms of the Creative Commons
Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it
is permissible to download and share the work provided it is properly cited. The
work cannot be changed in any way or used commercially without permission
from the journal.Excepto si se señala otra cosa, la licencia del ítem se describe como Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.